Business Wire

CA-QUALCOMM

5.3.2024 15:01:32 CET | Business Wire | Press release

Share
Qualcomm Increases Quarterly Cash Dividend

Qualcomm Incorporated (NASDAQ: QCOM) today announced that its Board of Directors has approved an increase in the Company’s quarterly cash dividend from $0.80 to $0.85 per share of common stock. This dividend increase will be effective for quarterly dividends payable after March 21, 2024 and will raise the annualized dividend payout to $3.40 per share of common stock.

Cristiano Amon, President and CEO of Qualcomm Incorporated, said, “We are pleased to announce an increase in our quarterly dividend. We remain committed to returning capital to stockholders through a balanced capital return policy, including a baseline of anti-dilutive stock repurchases.”

About Qualcomm

Qualcomm is enabling a world where everyone and everything can be intelligently connected. Our one technology roadmap allows us to efficiently scale the technologies that launched the mobile revolution – including advanced connectivity, high-performance, low-power compute, on-device intelligence and more – to the next generation of connected smart devices across industries. Innovations from Qualcomm and our family of Snapdragon platforms will help enable cloud-edge convergence, transform industries, accelerate the digital economy, and revolutionize how we experience the world, for the greater good.

Qualcomm Incorporated includes our licensing business, QTL, and the vast majority of our patent portfolio. Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, substantially all of our engineering and research and development functions and substantially all of our products and services businesses, including our QCT semiconductor business. Snapdragon and Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated. For more information, visit www.qualcomm.com.

Cautionary Note Regarding Forward-Looking Statements

In addition to historical information, this news release contains forward-looking statements. Such forward-looking statements speak only as of the date of this news release, and are based on our current assumptions, expectations and beliefs, and information currently available to us. These forward-looking statements, including but not limited to statements regarding our future dividend payments and our commitment to returning capital to stockholders through a balanced capital return policy, including a baseline of anti-dilutive stock repurchases, are inherently subject to risks and uncertainties. Past dividends and stock repurchases provide no assurance as to future dividends or stock repurchases, and the timing and amount of future dividends or stock repurchases, if any, could vary significantly in comparison both to past dividends or stock repurchases and to current expectations. Forward-looking statements are generally identified by words such as “estimates,” “guidance,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks” and similar expressions. Actual results may differ materially from those referred to in the forward-looking statements due to a number of important factors, including but not limited to: a deterioration in our future results of operations, financial condition, cash flows or business prospects; a determination by our Board of Directors that dividends or stock repurchases are not in the best interests of the Company and its stockholders; unexpected, unplanned or alternative requirements for, or uses of, our available cash, including but not limited to potential business acquisitions or other strategic transactions; legal or contractual restrictions on the payment of dividends or stock repurchases, including under credit agreements or other financing arrangements; changes in tax or other laws relating to dividends or stock repurchases; changes in general economic, business and political conditions; and other risks detailed in our Quarterly Report on Form 10-Q for the fiscal quarter ended December 24, 2023 filed with the Securities and Exchange Commission (SEC). Our reports filed with the SEC are available on our website at www.qualcomm.com. We undertake no obligation to update, or continue to provide information with respect to, any forward-looking statement or risk factor, whether as a result of new information, future events or otherwise.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240305537271/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CIG to Showcase How Next-Generation Broadband Is Driving More Value with PON, Wi-Fi, Optics, and Edge AI at Network X 2026, Booth C4.12.10.2026 09:11:00 CEST | Press release

From a full line of Wi‑Fi 8 Products to industrial Edge AI, CIG will demonstrate technologies designed to create more value across the network Cambridge Industries Group (CIG), a global leader in broadband and optical connectivity technologies, will showcase its latest broadband, optical, and Edge AI platform innovation at Network X 2026, October 13-15 in Vienna. The exhibit will focus on a practical challenge for network operators: how to increase capacity while improving the experience. CIG’s broadband showcase will span the network from fiber access to the connected home. Visitors will see live demonstrations of Wi-Fi 8 capabilities in an XGS-PON gateway, previewing CIG’s approach to next-generation Wi-Fi: greater flexibility in platform design and more dependable performance in real-world subscriber environments. CIG will also demonstrate its prplWare 4.2.1-certified Wi-Fi 7 device. CIG will also showcase the AIU-100 Edge AI controller, initially focused on manufacturing applicatio

Taxually Launches New E-Invoicing and Tax Calculation Products at Taxually Connect 202612.10.2026 09:00:00 CEST | Press release

More than 100 finance, tax and technology leaders gathered to explore where indirect tax compliance is heading in 2027 and beyond, as the company reports almost 40% growth in active clients Taxually, a leading global technology provider for indirect tax management, announced the launch of two new products for e-invoicing and tax calculation, together with new API capabilities, at Taxually Connect 2026. The full-day event, held on 29 September, brought together more than 100 finance, tax and technology leaders to discuss, debate and share views on where indirect tax compliance is heading in 2027 and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261012937592/en/ Taxually CEO and Co-Founder Stefan Mladenovic talking about next wave of e-invoicing mandates arriving in 2026 and EU-wide digital reporting coming in 2030. Both new products are designed as seamless extensions of Taxually’s existing platform. They are differe

Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome12.10.2026 08:00:00 CEST | Press release

Final analysis of 109 patients from 18 German centres demonstrates durable treatment outcomes in routine clinical practice1Median time-to-next-treatment(TTNT), the study's primary endpoint, was 14.9 months, alongside a 62.4% best overall response rate, 20.2-month overall median progression-free survival and improved quality of life from baseline reported in routine care1Exploratory analyses show meaningful responses in clinically relevant subgroups, including large cell transformation, folliculotropic mycosis fungoides and mogamulizumab-associated rash status, supporting individualised treatment for patients with mycosis fungoides and Sézary syndrome1 Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous

Megaport Expands Global Automated Infrastructure Platform Into Portugal12.10.2026 08:00:00 CEST | Press release

Megaport’s expansion to Portugal unlocks access to compute, network, and storage services for the local and global markets. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of its services in Portugal, expanding its European footprint and enabling enterprises and service providers in the region to connect instantly to the world’s leading cloud, network, and data center providers. With new on-ramps in Lisbon, customers in Portugal can now access Megaport’s automated infrastructure platform as well as more than 1,200 enabled data centers worldwide. This launch gives enterprises, MSPs, and carriers private, high-performance compute, network, and storage, as well as on-demand regional interconnection with scalable bandwidth. With Portugal’s data center market projected to reach US$3.09 billion by 2030 as well as Lisbon’s proximity to major submarine cable landings, the strengthening global connectivity hub is a natural

Filippo Fagnani from Quanta System Receives the EAU Award for Significant Contribution to Endourology at ICE 202610.10.2026 18:09:00 CEST | Press release

Filippo Fagnani, Marketing & Scientific Director of Quanta System’s Surgical Division, has been honoured with the Award for Significant Contribution to Endourology at ICE26, the International Conference on Endourology organised by the EAU Endourology Section. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010101303/en/ Filippo Fagnani receiving the prize with Olivier Traxer and Professor Bhaskar Somani. The recognition celebrates more than two decades of professional commitment to laser technology and a career built around a clear ambition: to translate the needs of urologists into increasingly precise, flexible and useful technologies, with the ultimate goal of supporting patient safety and better surgical outcomes. “I have always believed that technology should make the surgeon’s work more precise, more flexible and, most importantly, safer for the patient. My goal has never been to develop technology for its own sake,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye